Aequus Pharmaceuticals Inc. (AQS.V)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.96 Million CAD | -22.46% |
| 2022 | 3.64 Million CAD | -10.16% |
| 2021 | 4.05 Million CAD | 30.07% |
| 2020 | 3.11 Million CAD | -19.0% |
| 2019 | 3.85 Million CAD | -8.72% |
| 2018 | 4.21 Million CAD | -16.5% |
| 2017 | 5.05 Million CAD | -9.22% |
| 2016 | 5.56 Million CAD | 10.09% |
| 2015 | 5.05 Million CAD | 104.06% |
| 2014 | 2.47 Million CAD | 51.46% |
| 2013 | 1.63 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 612.42 Thousand CAD | -8.19% |
| 2024 Q2 | 736.56 Thousand CAD | 20.27% |
| 2023 Q1 | 733.41 Thousand CAD | 2.33% |
| 2023 Q2 | 685.23 Thousand CAD | -6.57% |
| 2023 Q4 | 667.05 Thousand CAD | -9.87% |
| 2023 Q3 | 740.07 Thousand CAD | 8.0% |
| 2023 FY | 2.82 Million CAD | -22.46% |
| 2022 Q4 | 716.69 Thousand CAD | -15.55% |
| 2022 Q2 | 1.07 Million CAD | -2.18% |
| 2022 Q1 | 1.09 Million CAD | 2.81% |
| 2022 FY | 3.64 Million CAD | -10.16% |
| 2022 Q3 | 848.68 Thousand CAD | -21.06% |
| 2021 Q2 | 1.03 Million CAD | 4.5% |
| 2021 Q4 | 1.06 Million CAD | 10.36% |
| 2021 FY | 4.05 Million CAD | 30.07% |
| 2021 Q1 | 987.18 Thousand CAD | -3.81% |
| 2021 Q3 | 968.63 Thousand CAD | -6.1% |
| 2020 FY | 3.11 Million CAD | -19.0% |
| 2020 Q3 | 675.36 Thousand CAD | 14.02% |
| 2020 Q2 | 592.34 Thousand CAD | -28.18% |
| 2020 Q1 | 824.77 Thousand CAD | -6.69% |
| 2020 Q4 | 1.02 Million CAD | 51.95% |
| 2019 Q2 | 1 Million CAD | -5.57% |
| 2019 FY | 3.85 Million CAD | -8.72% |
| 2019 Q3 | 917.01 Thousand CAD | -8.44% |
| 2019 Q1 | 1.06 Million CAD | 16.86% |
| 2019 Q4 | 883.86 Thousand CAD | -3.61% |
| 2018 Q4 | 907.67 Thousand CAD | -15.41% |
| 2018 FY | 4.21 Million CAD | -16.5% |
| 2018 Q2 | 1.04 Million CAD | -12.09% |
| 2018 Q3 | 1.07 Million CAD | 2.51% |
| 2018 Q1 | 1.19 Million CAD | 17.61% |
| 2017 Q1 | 1.3 Million CAD | -3.52% |
| 2017 FY | 5.05 Million CAD | -9.22% |
| 2017 Q4 | 1.01 Million CAD | -19.48% |
| 2017 Q3 | 1.25 Million CAD | -19.65% |
| 2017 Q2 | 1.56 Million CAD | 19.73% |
| 2016 Q1 | 1.28 Million CAD | -6.57% |
| 2016 FY | 5.56 Million CAD | 10.09% |
| 2016 Q2 | 1.5 Million CAD | 17.34% |
| 2016 Q4 | 1.35 Million CAD | -4.67% |
| 2016 Q3 | 1.42 Million CAD | -5.63% |
| 2015 Q1 | 1.11 Million CAD | -18.31% |
| 2015 Q4 | 1.37 Million CAD | -2.8% |
| 2015 FY | 5.05 Million CAD | 104.06% |
| 2015 Q3 | 1.41 Million CAD | 22.4% |
| 2015 Q2 | 1.15 Million CAD | 3.67% |
| 2014 Q4 | 1.36 Million CAD | 191.44% |
| 2014 FY | 2.47 Million CAD | 51.46% |
| 2014 Q3 | 467.81 Thousand CAD | 23.09% |
| 2014 Q1 | 266.06 Thousand CAD | -19.72% |
| 2014 Q2 | 380.04 Thousand CAD | 42.84% |
| 2013 FY | 1.63 Million CAD | 0.0% |
| 2013 Q4 | 331.4 Thousand CAD | 33.63% |
| 2013 Q3 | 248 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| CanadaBis Capital Inc. | 7.1 Million CAD | 58.294% |
| Decibel Cannabis Company Inc. | 40.44 Million CAD | 92.672% |
| Delivra Health Brands Inc. | 7.1 Million CAD | 58.307% |
| Entourage Health Corp. | 3.7 Million CAD | 20.06% |
| Lifeist Wellness Inc. | 17.59 Million CAD | 83.154% |
| Cannara Biotech Inc. | 15.34 Million CAD | 80.682% |
| Medicure Inc. | 13.98 Million CAD | 78.812% |
| PharmaCielo Ltd. | 8.33 Million CAD | 64.427% |
| Rubicon Organics Inc. | 14.22 Million CAD | 79.163% |
| BioSyent Inc. | 17.6 Million CAD | 83.167% |
| Voyageur Pharmaceuticals Ltd. | 1.22 Million CAD | -142.757% |